Glaukos Gross Margin 2014-2022 | GKOS

Current and historical gross margin for Glaukos (GKOS) over the last 10 years. The current gross profit margin for Glaukos as of September 30, 2022 is %.
Glaukos Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-09-30 $0.29B $0.22B 75.79%
2022-06-30 $0.29B $0.22B 76.47%
2022-03-31 $0.29B $0.23B 76.87%
2021-12-31 $0.29B $0.23B 76.87%
2021-09-30 $0.29B $0.22B 76.19%
2021-06-30 $0.28B $0.21B 74.65%
2021-03-31 $0.24B $0.16B 68.07%
2020-12-31 $0.23B $0.13B 59.56%
2020-09-30 $0.22B $0.13B 59.63%
2020-06-30 $0.21B $0.13B 63.21%
2020-03-31 $0.24B $0.18B 73.22%
2019-12-31 $0.24B $0.20B 83.61%
2019-09-30 $0.23B $0.20B 86.73%
2019-06-30 $0.21B $0.18B 86.73%
2019-03-31 $0.20B $0.17B 86.67%
2018-12-31 $0.18B $0.16B 86.19%
2018-09-30 $0.17B $0.15B 86.39%
2018-06-30 $0.17B $0.14B 86.67%
2018-03-31 $0.16B $0.14B 87.12%
2017-12-31 $0.16B $0.14B 87.42%
2017-09-30 $0.15B $0.13B 86.67%
2017-06-30 $0.14B $0.12B 86.43%
2017-03-31 $0.13B $0.11B 85.16%
2016-12-31 $0.12B $0.10B 85.22%
2016-09-30 $0.10B $0.09B 85.29%
2016-06-30 $0.09B $0.08B 84.62%
2016-03-31 $0.08B $0.07B 83.75%
2015-12-31 $0.07B $0.06B 81.94%
2015-09-30 $0.07B $0.05B 77.27%
2015-06-30 $0.06B $0.05B 76.27%
2015-03-31 $0.05B $0.04B 76.92%
2014-12-31 $0.05B $0.03B 75.56%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $2.458B $0.294B
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Edwards Lifesciences (EW) United States $50.772B 33.11
Alcon (ALC) Switzerland $37.369B 32.17
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.950B 40.42
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Nevro (NVRO) United States $1.410B 0.00
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00